Verge Genomics and Ferrer Announce Agreement to Co-Develop Clinical-Stage ALS Therapy VRG50635

SOUTH SAN FRANCISCO, Calif. and BARCELONA, Spain, March 25, 2024 (GLOBE NEWSWIRE) -- Verge Genomics, a leading clinical-stage biotechnology company, and Ferrer, an international B Corp pharmaceutical company with an increasing focus in rare neurological disorders, have announced a strategic…#barcelona #spain #vergegenomics #ferrer #bcorp #vrg50635 #verge #als #southeastasia #pikfyve
Source: Reuters: Health - Category: Consumer Health News Source Type: news